Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Improvements review found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://andyjkjdu.review-blogger.com/60405341/not-known-factual-statements-about-conolidin-to-replace-traditional-painkillers